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Abstract. An overview of the use of non-pr tein amino acids in the design of 
conformationally well-defined peptides, based on work from the author’s laboratory, 
is discussed. The crystal structures of several designed oligopeptides illustrate the use  
a-aminoisobutyric acid (Aib) in the construction of helices, D-amino acids in the 
design of helix termination segments and DPro–Xxx segments for nucleating of  
b-hairpin structures. b- and g-amino acid residues have been used to expand the range 
of designed polypeptide structures. 
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1. Introduction 
The ‘first principles’ approach to the design of polypeptide structures, which adopt well-
defined folded conformations, developed at Bangalore, relies on the use of stereo-
chemically constrained amino acids to direct peptide chain folding.1,2 The de novo design 
of polypeptide structures provides insights into the factors that govern the folding of 
peptides and proteins. The approach is based on the ability of specific non-protein amino 
acid residues to populate limited regions of conformational space, thereby serving as 
local nuclei for the propagation of ordered secondary structures. This overview presents 
the general background to the use of non-protein amino acids as stereochemical directors 
of polypeptide chain folding and illustrates some recent examples of the design of 
helices, hairpins and novel structures in sequences of mixed chirality. Recent work, 
which addresses the issue of enhanci g the repertoire of polypeptide structures by 
incorporating b- and g-amino acid residues, is also highlighted. 
2. Stereochemistry of polypeptide chains 
Forty years have passed since the principles of polypeptide conformational analysis were 
first enunciated by G N Ramachandran and his colleagues at the University of Madras.3 
The Ramachandran plot provides a remarkably powerful and convenient means for 
assigning the ‘stereochemical allowedness’ of the local conformations of individual 
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amino acid residues in polypeptide and protein structures. The variables used in the 
construction of the Ramachandran (f, y) plot are the two torsion (dihedral) angles f and 
y, which correspond to rotations about the two single bonds at each residue in the 
polypeptide chain, N–Ca (f) and Ca–C (y). The two-dimensional f, y plot simplifies the 
problem of considering three-dim nsional chain folding in analytical terms. The regular 
structures of polypeptide a-amino acid chains, the a-helix and b-sheet were first 
recognised by Linus Pauling, a little over half a century ago.4 In the Ramachandran 
representation, an idealised secondary structure, generat d by repetition of the f, y 
dihedral angles along the chain, is simply a single point in f, y space. The allowed 
regions of conformational space were generated by Ramachandran’s group assuming the 
simple hard sphere contact criterion, which simply states that two proximal non-bonded 
atoms cannot approach one another at distances less than the sum of their van der Waals 
radii. Figure 1a shows a view of the classical Ramachandran plot for the L-alanine
residue, with the regions of major regular structures indicated.3,5,6 It is clear that almost 
two thirds of f, y space is strictly disallowed for L-Ala, the prototype chiral amino acid. 
This map is broadly representative of the allowed regions for 18 of the 20 amino acids 
 
 
 
 
Figure 1. (a) Ramachandran map for N-acetyl-L-Ala-N¢-methylamide. The shaded 
regions are stereochemically allowed. Regions corresponding to 310, a-helical and 
parallel (­­) and antiparallel (­¯) b-sheets are indicated. (b) Distribution of f, y 
values of Gly residues from 250 protein structures (£ 2×0 Å  resolution) (ref. 7b). (c) 
Distribution of non-Gly residues from 250 protein structures (ref. 7b).
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that occur in proteins, the exceptions being glycine and proline. For Gly, the sole achiral 
residue in proteins, which la ks a substitutent at the Ca atom, the allowed regions of f, y 
space are considerably larger and symmetrically disposed with respect to the origin 
(figure 1b). The distribution of experimentally determined f, y values for individual 
residues in high resolution protein structures, 47612 residues from 250 proteins, is shown 
in figure 1c. Clearly, the experimental observations closely correspond to the allowed 
regions anticipated by Ramachandran. A similar distribution for Gly residues is illu-
strated in figure 1b. Notably, for this achiral residue the observed distribution is spread in 
all four quadrants of the , y map.7 Inspection of figures 1b and c reveals that alkylation 
at the Ca atom dramatically reduces the allowed regions of conformational space, on 
going from Gly to L-Ala. By extrapolation, further alkylation, as in the Ca,a dialkylated 
residue a-aminoisobutyric acid (Aib) [H2N–C(CH3)2–COOH], would result in a greater 
restriction of the allowed conformational space. In principle, the allowed regions f r the 
Aib residue can be generated by overlapping the Ramachandran maps for L-Ala and  
D-Ala (figure 2a).8 It is apparent that only small regions that correspond to the right- and 
left-handed helical structures are indeed allowed for this residue.9,10 
3. a-Aminoisobutyric acid and helix nucleation 
Aib is a naturally occurring amino acid, which is widely distributed in polypeptide 
antibiotics produced by diverse species of soil fungi. Interestingly, Aib and its homolog 
isovaline (Iva) [H2N–C(CH3)(C2H5)–COOH] are components of the amino acid mixtures 
found in meteorites and have been used as an indicator of the extraterrestrial origin of 
rock samples.11 The peptaibol class of antibiotics produced by several fungal strains are 
characterised by a high proporti n of Aib residues in the sequence and a C-terminal 
alcohol moiety. A very large number of peptaibol antibiotics have thus far been chara-
cterised12 and the crystal structures of alamethicin,13 zervamicin,14 and antiamoebin15,16 
have been determined. The structures of the natural peptides are largely helical even  
 
 
 
 
Figure 2. (a) Overlapped Ramachandran maps for N-acetyl-L-Ala-N¢-methylamide 
and N-acetyl-D-Ala-N¢-methyamide. The shaded regions are stereochemically allowed 
for both L- and D-Ala. (b) Distribution of the observed conformations of 1104 Aib 
residues in 367 independent crystal structures. (Coordinates for peptide structures 
have been obtained from the Cambridge Crystallographic Data Centre, ref. 72.) 
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when the sequences are interspersed with several Pro/Hyp residues; testimony to the helix 
promoting properties of the Aib residue. Interest in the structural chemistry of the 
peptaibol antibiotics has stemmed from the fact that they form voltage gated ion channels 
across artificial lipid bilayers.17 
 The stereochemical consequences of introducing Aib into peptide chains was first 
established at Bangalore, with the crystal structure determination and solution spectro-
scopic studies of the N-terminus tetrapeptide sequence of alamethicin.18 This was 
followed by the establishment of a 310-helical conformation for the Aib oligopeptide 
Tosyl–(Aib)5–OMe in crystals.
19 Almost concurrently, results of investigations of Aib 
containing sequences corresponding to fragments of peptaibol antibiotics appeared from 
the groups of Garland Marshall (St Louis)20 and Gunther Jung (Tubingen),21 providing 
strong support for the helix forming properties of Aib residues. It was quickly realised 
that the introduction of Aib residues into polypeptide chains limits the range of accessible 
conformations; nucleates of b-turns and helical structures and facilitates crystallisation 
presumably by restricting conformational flexibility in solution. Over the last 20 years a 
very large number of Aib containing peptides crystal structures have been determined, 
primarily by groups at Bangalore, Washington (Isabella L Karle) and Padova (Claudio 
Toniolo), which have provided valuable insights into the nature of helical conformations, 
helix packing in crystals, helix hydration, 310/a-helical transitions and the role of intra-
molecular hydrogen bonds in helix stabilisation. The extensive work on Aib peptides has 
resulted in the accumulation of a large body of information on polypeptide 
conformations.1,2,22 Figure 2b shows the distribution of the observed f,y values for Aib, 
representing 1104 residues from 367 independent crystal structures. A dramatic con-
centration of f, y values in the right (aR) and left handed (aL) helical regions emphasizes 
the great propensity of Aib residues to occur in heli al conformations. In the following 
section we briefly consider some specific issues related to helical structures in poly-
peptides. 
4. 310 and a-helical structures 
Figure 3 illustrates the molecular conformation in crystals observed in three representa-
tive Aib containing decapeptides. The Aib oligomer pBrBz–(Aib)10–OtBu adopts an 
almost perfect 310 helical conformation stabilised by eight intramolecular 4 ® 1 
hydrogen bonds.23 The decapeptide Boc–Aib–(Ala–Leu–Aib)3–OMe adopts a mixed 310/ 
a-helical structure with 4® 1 hydrogen bonds (310) favored at the N-terminus and 5 ® 1 
hydrogen bonds (a) occurring at the C-terminus.24 The decapeptide Boc–Leu–Aib–Val–
Ala–Leu–Aib–Val–Ala–Leu–Aib–OMe adopts an almost perfect a-helical conformation 
stabilised by seven intramolecular 5 ® 1 hydrogen bonds.25 Table 1 summarises the 
potential 4® 1 and 5 ® 1 hydrogen bond parameters, which permit the choice of the 
interaction corresponding to either 310 or ahelical structures. It must be emphasised that 
the distinction betwen 310, a and mixed helical structures is generally based only on the 
choice of the intramolecular hydrogen bond type. Relatively small variations in f, y 
dihedral angles can result in switching of 4 ® 1 and 5 ® 1 hydrogen bonds. In helices 
the NLO distances for both 4 ® 1 and 5 ® 1 hydrogen bonds can lie within acceptable 
limits (£ 3×5 Å ). It is therefore necessary that the complete characterisation of the donor 
acceptor geometries are carried out before choosing the type of hydrogen bond.26 There 
has been considerable discussion in the literature on the relative stabilities of 310 nd  
a- helical structures in Aib containing peptides.27 The general consensus that has 
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emerged is that in Aib oligomers, 310 helices are favoured. In sequences, which contain 
relatively few Aib residues, mixed 310/a-helical structures and -helical structures appear 
to be prominent.22c A survey of a large body of helical structures does not reveal any 
readily apparent correlation between the Aib content and positioning in the seque ce, in 
the case of peptides having fewer than 50% Aib residues. In several crystal structures, 
multiple helical molecules have been observed in the crystallographic asymmetric unit, 
which adopt different hydrogen bonding patterns.22c,e,f,28 It appears that the activation 
barriers required for the transformation of 310 helical turns into a-helical turns is small, 
facilitating facile interconversion in solution. Attempts to establish diagnostic spectro-
scopic criteria, for example CD band shapes and positions29 are likely to be complicated 
by dynamic interconversions between heterogeneous helical structures. The crystalline 
state may be viewed as providing a snapshot of specific of the molecular conformations 
that are present in solution, often entrapping a single distinct molecular species. The 
observation of multiple helical forms in crystals underscores the fact that the molecules 
probably exist in a broad potential well, with very small barriers separating various 
helical forms. 
 
 
 
Figure 3. Molecular conformations observed in the crystals for three synthetic 
decapeptides (a) pBrBz–(Aib)10–OtBu, 310-helix (ref. 23). (b) Boc–Aib–(Ala–Leu–
Aib)3–OMe, 310/a helix (ref. 24). (c) Boc–Leu–Aib–Val–Ala–Leu–Aib–Val–Ala–
Leu–Aib–OMe, a-helix (LAL10, ref. 25). Dotted lines represent intramolecular 
hydrogen bonds. 
S Aravinda et al 378 
 
 
   
T
a
b
le
 1
. 
P
o
te
n
ti
a
l 
h
y
d
ro
g
e
n
 b
o
n
d
 p
a
ra
m
e
te
rs
a  
in
 t
h
re
e
 m
o
d
e
l 
h
e
lic
a
l 
d
e
ca
p
e
p
ti
d
e
s.
 
  
In
tr
a
m
o
le
cu
la
r
 
Id
e
a
l 
3 10
-h
e
lix
  
M
ix
e
d
 3 1
0/a
-h
e
lix
 
Id
e
a
l a
-h
e
lix
 
 T
y
p
e 
D
o
n
o
r 
A
cc
e
p
to
r 
N
L
O
 (
Å
) 
H
L
O
 (
Å
) 
N
–H
L
O
 (
d
e
g
) 
N
L
O
 (
Å
) 
H
L
O
 (
Å
) 
N
–H
L
O
 (
d
e
g
) 
N
L
O
 (
Å
) 
H
L
O
 (
Å
) N
–H
L
O
 (
d
e
g
) 
 4 
®
 1
 
N
 (
3)
 
O
 (
0
) 
2×
9
4
5·  
2×
1
2
3
  
1
5
9×8
 
2×
8
7
9·  
2×
0
9
2 
1
5
1×8
 
3×
5
5
9 
3×
1
0
4 
1
1
5×4
 
4 
®
 1
 
N
 (
4
) 
O
 (
1
) 
2×
9
7
5·  
2×
1
8
2 
1
5
3×4
 
3×
0
6
5·  
2×
2
4
0 
1
6
0×6
 
3×
2
0
0 
2×
7
7
9 
1
1
1×8
 
4 
®
 1
 
N
 (
5
) 
O
 (
2
) 
2×
9
7
9·  
2×
1
9
8 
1
5
1×1
 
5×
0
4
6 
4×
2
5
3 
1
5
5×2
 
3×
4
0
1 
2×
9
2
0 
1
1
7×3
 
4 
®
 1
 
N
 (
6
) 
O
 (
3
) 
3×
1
7
9·  
2×
3
8
2 
1
5
4×4
 
2×
9
6
6·  
2×
3
8
8 
1
2
5×0
 
3×
2
2
1 
2×
8
5
5 
1
0
7×5
 
4 
®
 1
 
N
 (
7
) 
O
 (
4
) 
3×
0
2
0·  
2×
1
8
3 
1
6
4×2
 
3×
3
7
7 
3×
0
0
1 
1
0
8×8
 
3×
3
9
3 
2×
9
2
3 
1
1
6×3
 
4 
®
 1
 
N
 (
8
) 
O
 (
5
) 
3×
2
1
1·  
2×
3
5
5 
1
7
3×4
 
3×
4
2
1 
2×
9
3
7 
1
1
7×6
 
3×
2
8
3 
2×
8
8
4 
1
1
0×3
 
4 
®
 1
 
N
 (
9
) 
O
 (
6
) 
3×
0
5
7·  
2×
2
2
5 
1
6
3×0
 
3×
2
2
7 
2×
6
3
2 
1
2
7×4
 
3×
3
9
0 
2×
9
3
2 
1
1
5×3
 
4 
®
 1
 
N
 (
1
0
) 
O
 (
7
) 
2×
9
0
7·  
2×
0
8
7 
1
5
9×2
 
4×
1
8
8 
3×
7
5
9 
1
1
4×4
 
3×
2
3
5 
2×
7
8
2 
1
1
4×5
 
 5 
®
 1
 
N
 (
4
) 
O
 (
0
) 
4×
6
1
3 
3×
9
1
6 
1
4
0×7
 
3×
5
9
7 
3×
3
2
9 
1
0
1×3
 
2×
9
7
8·  
2×
1
6
5 
1
5
7×7
 
5 
®
 1
 
N
 (
5
) 
O
 (
1
) 
4×
3
3
7 
3×
6
6
5 
1
3
7×3
 
5×
2
0
0 
4×
6
3
3 
1
2
7×4
 
3×
1
1
3·  
2×
2
7
7 
1
6
3×9
 
5 
®
 1
 
N
 (
6
) 
O
 (
2
) 
4×
3
3
1 
3×
6
3
0 
1
4
0×8
 
6×
0
0
1 
5×
1
5
7 
1
6
8×0
 
3×
0
7
1·  
2×
2
3
7 
1
6
3×3
 
5 
®
 1
 
N
 (
7
) 
O
 (
3
) 
4×
6
0
0 
4×
0
1
2 
1
2
8×8
 
3×
2
0
9·  
2×
3
5
9 
1
6
9×7
 
3×
0
0
5·  
2×
1
7
4 
1
6
2×1
 
5 
®
 1
 
N
 (
8
) 
O
 (
4
) 
4×
7
9
1 
4×
1
8
1 
1
3
1×2
 
3×
0
8
9·  
2×
3
0
1 
1
5
2×4
 
3×
0
1
4·  
2×
1
8
3 
1
6
2×3
 
5 
®
 1
 
N
 (
9
) 
O
 (
5
) 
5×
2
0
0 
4×
5
4
7 
1
3
6×0
 
3×
1
4
5·  
2×
3
7
9 
1
4
8×6
 
3×
0
4
8·  
2×
2
0
9 
1
6
5×2
 
5 
®
 1
 
N
 (
1
0
) 
O
 (
6
) 
4×
6
0
0 
3×
9
7
0 
1
3
3×0
 
2×
9
2
5·  
2×
0
8
4 
1
6
5×4
 
2×
9
8
6·  
2×
1
9
4 
1
5
3×0
 
a A
v
e
ra
g
e
 h
y
d
ro
g
e
n
 b
o
n
d
 p
a
ra
m
e
te
rs
 r
e
p
o
rt
e
d
 f
o
r 
p
o
ly
p
e
p
ti
d
e
 h
e
lic
e
s 
b
a
se
d
 o
n
 a
n
a
ly
si
s 
o
f 
p
ro
te
in
 c
ry
st
a
l 
st
ru
ct
u
re
s 
a
re
 3
1
0-h
e
lix
 (
4 ®
 1
),
 N
L
O
 =
 3
×0
5 
Å
, 
H
L
O
 =
 2
×1
7 
Å
, Ð
N
–H
L
O
 =
 1
4
9°
; a
-h
e
lix
 (
5 ®
 1
),
 N
L
O
 =
 2
×9
9 
Å
, 
HL
O
 =
 2
×0
6 
Å
, Ð
N
–H
L
O
 =
 1
5
5°
 (
re
f.
 2
6
a
)
 
· T
h
e
se
 a
re
 t
h
e
 a
cc
e
p
ta
b
le
 h
y
d
ro
g
e
n
 b
o
n
d
s
 
  
Non-protein amino acids in peptide design 379 
5. Helix-terminating motifs 
The ability to synthetically construct defined helical peptide modules has permitted 
structural investigation of helix-terminating motifs. In proteins, right-handed a-helical 
segments often terminate with a residue adopting the left-handed h lical (L) confor-
mation (Schellman motif).30 The achiral residue Gly has the greatest propensity to occur 
at the terminating (T) position. In helical peptides containing an achiral Aib residue at the 
penultimate position from C-terminus, formation of Schellman motifs, with Aib adopting 
an aL conformation, has been frequently observed.31 In th se structures, pairs of hydrogen 
bonds 6 ® 1 and 4® 1 stabilise the helix terminating motif (figure 4). 
 As a part of a program to construct synthetic sequences containing multiple elements 
of secondary structure, we examined approaches to terminate helices at the C-terminus 
end. The introduction of D-amino acid residues, which favour L conformations should 
facilitate helix termination. Figure 5 shows the molecular conformation in crystals of the 
decapeptide Boc–Leu–Aib–Val–Ala–Leu–Aib–Val–DAla–DLeu–Aib–OMe, (LAD10), 
which possesses two contiguous D-residues at positions 8 and 9. As anticipated, the right-
handed helix formed by residues 1 to 7 terminated with DAla(8) adopting an L confor-
mation, generating a Schellman motif. However, this structure revealed an unanticipated 
feature with polypeptide chain reversal occurring over the C-terminus segment, residu s 
8 to 10, stabilised by an unusual C–HLO hydrogen bond between Ala(4)CaH and 
DLeu(9) CO groups.32 An almost identical conformation is also established in crystals of 
the analog peptide LGD10, where Ala(4) is replaced by Gly. In this case, the intra-
molecular C–HLO hydrogen bond involved the pro R hydrogen of the Gly residue.33  
 
 
 
 
Figure 4. (a) Helix terminating Schellman motif stabilized by a pair of 4 ®1 nd 
6 ® 1 hydrogen bonds. Residue T is the helix terminating residue. Residue T-1 to T-4 
form the C-terminus of the helix. (b) Molecular conformation in crystals for the 
peptide Boc–Leu–A ib–Val–Ala–Leu–Aib–Val–OMe (ref. 31c). Note the formation of 
the Schellman motif. Aib(6) adopts an aL conformation and is the terminating residue 
T. (c) An overlay of helix terminating Schellman motifs observed in 18 crystal 
structures of helical peptides. 
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Figure 5. Molecular conformation of the decapeptide Boc–Leu–Aib–Val–Ala–Leu–
Aib–Val–DAla–DLeu–Aib–OMe (LAD10, ref. 32) observed in crystals. Note the for-
mation of the C–HLO hydrogen bond between Ala(4)CaH and DLeu(9) CO groups. 
 
 
Figure 6a shows the superposition of peptides LAD10 and LGD10 (RMSD = 0×54 Å  for 
all the back bone atoms). A notable feature of this unusual motif is that it appears to 
facilitate registry of antiparallel helix and strand segments, stabilised by backbone  
C–HLO hydrogen bonds. A search of 634 high resolution protein structures revealed the 
occurrence of a similar motif in proteins. Figure 6b shows the superposition of 15 
examples from protein structures on the structure of peptide LAD10.34 Th  role of the  
C–HLO hydrogen bond in facilitating the novel chain reversal in peptides LAD10 and 
LGD10 has been established by determining the structures of two peptide analogs Boc–
Leu–Aib–Val–DAla–Leu–Aib–Val–DAla–DLeu–Aib–OMe (DA10) and Boc–Leu–Aib–
Val–Aib–Leu–Aib–Val–DAla–DLeu–Aib–OMe (LUD10).31 In these two cases, the pro R 
CaH at T-4 has been replaced by a methyl group. Figure 7 shows a view of the molecular 
conformation of DA10 and LUD10 in crystals. Interestingly, both the peptides adopt 
conformations which are completely distinct from those observed for LAD10 and 
Non-protein amino acids in peptide design 381 
LGD10, underscoring the importance of the interaction involving the T-4 CaH group in 
determining the overall fold of the molecule. This example illustrates the role of a 
relatively long-range backbone interaction in determining peptide folding. 
6. Residue and helix chirality 
The availability of crystalline helical peptides generated by introducing Aib residues into 
sequences of L-amino acids has permitted the creation of novel backbone folds, which are 
not observed in protein structures. Figure 8 illustrates the crystal structures of two 
enantiomeric 14 residue peptides, generated by fusing helical sequences of opposite 
chirality. The peptides Boc–D–(Val–Ala–Leu–Aib–Val–Ala–Leu)–L–(Val–Ala–Leu–
Aib–Val–Ala–Leu)–OMe (DL14)35 and Boc–L–(Val–Ala–Leu–Aib–Val–Ala–Leu)–D–
(Val–Ala–Leu–Aib–Val–Ala–Leu)–OMe (LD14)36 were synthesised by condensation of 
the helical module Boc–Val–Ala–Leu–Aib–Val–Ala–Leu–OMe (UV7),37 and its enantio-
mer. Notably, the two enantiomeric 14 residue sequences crystallise in polymorphic 
forms DL14 (space group = P43); LD14 (space group = P21, two molecules in the 
asymmetric unit); providing a view of three independent ‘ambidextrous’ structures. 
Figure 9 shows a schematic ribbon diagram of this unusual fold. The view down the helix  
 
 
 
 
Figure 6. (a) Superposition of the crystal state conformations of the peptides Boc–
Leu–Aib–Val–Ala–Leu–Aib–Val–DAla–DLeu–Aib–OMe (LAD10) and Boc–Leu–
Aib–Val–Gly–Leu–Aib–Val–DAla–DLeu–Aib–OMe (LGD10), (ref. 33). (b  Overlay 
of 15 C–HLO hydrogen bond stabilised helix terminating motifs observed in protein 
structures with LAD10 (ref. 34a).
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Figure 7. Molecular conformation in crystals for two synthetic decapeptides (a) 
Boc–Leu–Aib–Val–DAla–Leu–Aib–Val–DAla–DLeu–Aib–OMe (DA10). Two mole-
cules are observed in the crystallographic asymmetric unit. (b) Boc–Leu–Aib–Val–
Aib–Leu–Aib–Val–DAla–DLeu–Aib–OMe (LUD10). Note the difference in the 
observed structures of these peptides as compared to the decapeptides illustrated in 
figure 6a. 
 
 
axis illustrates the lateral displacement of the two helices. At the chiral junction, the 
fusion of N- and C-terminal helices of opposite hands is mediated through the formation 
of a Schellman motif. While polypeptides containing fused helical segments of opposite 
chirality have no natural analog at present, the possibility that such structures may find 
application is enhanced by recent studies of chiral conflict in synthetic polymers.38 
 The introduction of single D-amino acids or double D-segments into L-amino acid 
sequences has been anticipated to destabilise right handed helical structures. In the highly 
stable helical folds nucleated by Aib residues, D-amino acids can be accommodated into 
aR conformations and conversely L-amino acids can be induced to adopt aL c nfor-
mations. The recent crystal tructure determinations of predominately L-amino acid 
sequences containing guest D-r idues illustrate this point. Figure 10 shows the molecular 
conformation of a 13-residue peptide Boc–Leu–Aib–Val–Ala–Leu–Aib–Val–DAla–
DLeu–Aib–Leu–Aib–Val–OMe (LUV13). In this case the double D-s gment DAla–DLeu 
is comfortably accommodated in a continuous right handed helical structure [DAla(8) 
f = –49×3°, y = –48×9°; DLeu(9) f = –56×1°, y = –54×9°].39 In the structure of decapeptide 
DA10 (figure 7a) the DAla(4) residue occurs in an aR conformation [f = –46×6°, y = 
–52×9° for molecule A and f =–54×1°, y = –48×6° for molecule B] with the segment 
residues 1 to 7 forming a conventional right handed helix. In the decapeptide LUD10 
(figure 7b), the N-terminal helix terminates at Aib(6) with the segment 6 to 9 residue 
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forming left handed helix. LVal(7) adopts an L conformation [f= 42×5°, y = 40×0°]. 
These examples point to the use of designed host helical sequences in investigating the 
effect of introduction of guest residues of opposite chirality. 
7. D-Proline and the nucleation of b-hairpins 
The recognition that the introduction of local conformational constrains can induce the 
formation of well defined structures in oligopeptides suggests that stereochemical control 
over polypeptide chain folding may be achieved by judicious introduction of amino acids  
 
 
 
 
Figure 8. Molecular conformation in crystals observed for peptide sequences 
containing fused segments of opposite chirality. (a) Boc–D–(Val–Ala–Leu–Aib–Val–
Ala–Leu)–L–(Val–Ala–Leu–Aib–Val–Ala–Leu)–OMe (DL14). (b) Boc–L–(Val–Ala–
Leu–Aib–Val–Ala–Leu)–D–(Val–Ala–Leu–Aib–Val–Ala–Leu)–OMe (LD14). Two 
molecules observed in the asymmetric unit are shown. In all cases, hydration is 
observed at the centre of the molecule corresponding to the chiral junction (refs 35, 
36). 
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Figure 9. Ribbon representation of the ambidextrous helices shown in figure 8. 
(Top) View perpendicular to helix axis. (bottom) View down the helix axis showing 
the lateral displacement of the helical segments. 
 
 
with definite conformational properties, into host L-amino acid sequences. This principle 
has been illustrated in the preceding section for the design of helical peptides. The  
b-hairpin constitutes a simple structural motif in which two antiparallel strands are stabi-
lised by cross- trand hydrogen bonds. An analysis of protein structures by Janet Thornton 
and her colleagues suggested that hairpins in proteins are often nucleated by two residue 
b-turns (tight turns).40 Most frequently, b-turns of type II¢ or I¢ form the nucleus for chain 
reversal. The ‘prime’ turns require a positive f alue (» +60°), for the i + 1 residue. In 
proteins, Gly often occupies this position. The other residue predominately found s Asn, 
which has a fairly high propensity for adopting conformations with positive f values.41 In 
synthetic design it is necessary to fix the stereochemistry of the turn segment in order to 
nucleate antiparallel hairpins. Figure 11a shows the allowed region of the Ramachandran 
map for LPro and DPro. In these residues, constraints of pyrrolidine ring formatio  restrict 
the value of f to a narrow band, centred around 60°. The preferred f value for LPro is  
–60° ± 20°, while in DPro the corresponding value is +60° ± 20°. Figure 11b summaries 
the observed conformation for proline residues in a representative dataset of proteins.7 
Two strong clusters are observed corresponding to f = –60°, y= –30° and f = –60°, 
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y = +120°, which are the values required at the i + 1 position of type I and II b-turns, 
respectively. We may therefore draw the inference that the enaniomeric residue DPro will 
favour conformations which correspond to the i +1 position in type I¢ and II¢ b-turns. The 
use of DPro–Xxx segments to nucleate b-hairpin structures in peptides was developed at 
Bangalore1 and independently in the group of Sam Gellman at Madison.42 Spectroscopic 
investigation of the octapeptide Boc–Leu–Val–Val–DPro–Gly–Leu–Val–Val–OMe first  
 
 
 
 
 
Figure 10. Molecular conformation in crystals of a 13-residue peptide helix Boc–
Leu–Aib–Val–Ala–Leu–Aib–Val–DAla–DLeu–Aib–Leu–Aib–Val–OMe (LUV13, ref. 
39) containing a centrally positioned DAla(8)–DLeu(9) double D-segment. 
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Figure 11. (a) The allowed regions in Ramachandran space for LPro and DPro 
residues (ref. 2). Note that the torsion angle f is restricted to a relatively narrow range 
of f values. LPro = –60 ± 20°; DPro = +60 ± 20°. (b) Observed distribution of con-
formational angles for 4995 Pro residues in 538 protein crystal structures (ref. 7b). 
 
 
 
 
 
Figure 12. Molecular conformation in crystals observed for two synthetic octa-
peptides (a) Boc–Leu–Val–Val–DPro–Gly–Leu–Val–Val–OMe (ref. 44). (b) Boc–
Leu–Val–Val–DPro–Ala–Leu–Val–Val–OMe (ref. 45), Note there are two indepen-
dent molecules in the asymmetric unit, havi g similar conformations; only one is 
shown. 
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Figure 13. Molecular conformation in crystals observed for the octapeptide Boc–
Leu–Phe–Val–Aib–DAla–Leu–Phe–Val–OMe (UDA8, ref. 49). The Aib-DAla seg-
ment forms a type I¢ b-turn. 
 
 
revealed the formation of a stable hairpin in solution, as evidenced by the observation of 
all diagnostic interstrand nuclear Overhauser effects (NOEs).43 The subsequent crystal 
structure determination revealed two independent molecules in the crystallographic 
asymmetric unit, both of which adopted a b-hairpin conformation with the DPro–Gly 
segment forming a type II¢ b-turn.44 Figure 12 illustrates the molecular conformation in 
crystals, determined by X-ray diffraction, for the two octapeptides Boc–Leu–Val–Val–
DPro–Gly–Leu–Val–Val–OMe and Boc–Leu–Val–Val–DPro–Ala–Leu–Val–Val–OMe, 
which contain centrally positioned, turn nucleating DPro–Xxx segments.45b-hairpins have 
also been demonstrated in crystals for peptides Boc–Leu–Val–Val–DPro–Gly–Leu–Phe–
Val–OMe, Boc–Leu–Phe–Val–DPro–Ala–Leu–Phe–Val–OMe, Boc–Met–Leu–Phe–Val–
DPro–Ala–Leu–Val–Val–Phe–OMe, Boc–Leu–Val–Val–DPro–Aib–Leu–Val–Val–OMe, 
Boc–Leu–Phe–Val–DPro–Ac8c–Leu–Phe–Val–OMe. In all cases, the central 
DP o–Xxx 
segment adopts type II¢ turn conformations (unpublished). These crystallographic 
investigations establish the simple principle of nucleating stable hairpins by inserting 
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DPro–Xxx segments into L-amino acid sequences. The extension of this approach to the 
design of three-, four- and five-stranded b-sheet structures has been achieved by the 
insertion of multiple DPro–Xxx segments into designed peptide chains. Thus far, the 
characterisation of multi stranded b-sheets has been achieved in solution by two-
dimensional NMR methods.1,46 The largest sheet like structure achieved by synthetic 
design has been an eight stranded b-sheet in a 70 residue C2 symmetric polypeptide, 
stabilised by a single disulfide bond.47 The search for alternative hairpin nucleating seg-
ments has encompassed both protein and non-protei  amino acids. Asn–Gly sequences 
have been successfully employed in generating single b-hairpins and three stranded  
b-sheet structures characterised by NMR spectroscopy in solution.48 We have explored 
the possibility of using Aib–DXxx sequences to nucleate type I¢ b-turns (310 helical turns). 
Figure 13 shows the molecular conformations in crystals of a designed octapeptide Boc–
Leu–Phe–Val–Aib–DAla–Leu–Phe–Val–OMe, which reveals a b-hairpin conformation 
nucleated by an Aib–DAla type I¢ b-turn. In this structure, cross-strand aromatic 
interactions between the Phe residues at position 2 and 7 (centroid to centroid distance for 
aromatic rings is 5×52 Å ) may lend further stability to the observed structure.49 Several 
recent investigations address the issue of stabilising b-hairpin conformations by specific 
cross-strand interactions between aromatic side chains. This approach is of particular 
relevance in the design of stable sheet like structures in water where hydrophobic 
clustering of side chains may lend additional stability to the design of backbone folds.50 
 
 
 
 
Figure 14. Molecular conformation in crystals for the synthetic 17-residue peptide 
Boc–Val–Ala–Leu–Aib–Val–Ala–Leu–Gly–Gly–Leu–Phe–Val–DPro–Gly–Leu–Phe–
Val–OMe (ref. 52). (a) Note the two distinct secondary structure segments residues  
1–7 form a helix, while residues 10–17 form a hairpin. (b) Ribbon representation 
illustrating the orientation of the two secondary structures.
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Figure 15. A comparison of the helical structures formed by poly a-peptides and 
poly b-peptides. (a) and (b) correspond to the 310 and a-helical structures observed in 
polypeptides formed by a-amino acids. (c) 12-helix formed in the crystal structure of 
an oligomer of the b-amino acid ACPC (ref. 59). (d) 14-helix formed in the crystal 
structure of an oligomer of the b-amino acid ACHC (ref. 60). A view perpendicular to 
the helix axis is shown on top. The lower figures are a view down the helix axis.
8. Mixed a/b structures 
Well-defined modules of secondary structure (a and b) have been combined in synthetic 
peptides to yield mixed ab structures. The existence of distinct helix and hairpin seg-
ments have been demonstrated in the 17 residue sequence, Boc–Le –Aib–Val–Ala–Leu–
Aib–Val–Gly–Gly–Leu–Val–Val–DPro–Gly–Leu–Val–Val–OMe, although NMR studies 
were unable to clearly define the relative orientation of the two modules.51 The related 17 
residue peptide, Boc–Val–Ala–Leu–Aib–Val–Ala–Leu–Gly–Gly–Leu–Phe–Val–DPro–
Gly–Leu–Phe–Val–OMe, yielded single crystals permitting X-ray diffraction studies, 
which established a right-handed helical segment spanning residues 1 to 7, terminating in 
a Schellman motif with residue 8 at position T. The segment 10–17 forms a b-hairpin 
nucleated by a type II¢ b-turn, with DPro–Gly as the corner residues (figure 14).52 
Building in greater f, y restrictions at the linking segments between secondary structures 
may permit greater control on the orientation of the helix and strand modules. 
9. b- and g-amino acid residues in peptides 
The stereochemistry of peptides and polypeptides containing omega amino acids has 
been reviewed, with specific attention to early studies on homopolymers.53 In b-amino 
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Figure 16. Nomenclature for b- esidues. 
 
 
Figure 17. Observed b-residue conformations in crystal structures of synthetic 
peptides representing on a three-dim nsional f–q–y plot. The coloured planes 
correspond to the gauche conformation about Ca–Cb bonds. * (black): achiral acyclic 
unsubstituted b-amino acid, b-glycine (3-amino propionic acid); o (yellow): acyclic 
substituted b-amino acids; à (green): chiral cyclic b-amino acids;  (blue): nipecotic 
acid;  ( pink): idealised 12- and 14-helices. 
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Figure 18. Location of the regions of ordered secon ary structures for b-residues in 
f–q–y space. The a-helix and b-sheet are the classical structures for poly a-amino 
acids. b-residues occurring in the appropriate shaded region can be accommodated 
without disruption of secondary structures. The 12-helix and 14-helix are well 
characterised secondary structures for poly b-pe tides.  
 
acid residues the introduction of an additional degree of torsional freedom (q) into the 
backbone is expected to enhance conformational flexibility. Helical structures have been 
postulated for poly(a-alkyl-b-aspartates) on the bases of fibre diffraction, polarised IR 
spectroscopy and molecular mechanics and quantum chemical calculations by Munoz-
Guerra, Subirana, Alemann and coworkers.54 Int rest in the conformations of b-peptides 
received a dramatic boost with the work of Dieter Seebach55 and S m Gellman56 which 
established, unequivocally, the ability of oligopeptides containing b-residues to fold into 
helical conformations, which are completely distinct from those adopted by a-peptid s. 
Figure 15 illustrates the well characterised helical forms observed in poly a- and poly  
b-peptides. The flood of recent research in the area of b- and g-peptides has been 
facilitated by the synthetic accessibility of many chiral, multiply substit ted b- and g-resi-
dues.57 Figure 16 defines the general formulae for b- mino acids and the nomenclature 
used for representing substituted residues. The structures of three cyclic b-amino a ids in 
which rotation about the central Ca–Cb bond (q) is restricted are also shown. The 
formation of folded structures in b-peptides immediately suggests that these residues may 
be used to expand the range of designed peptide conformations, particularly when used in 
conjunction with stereochemically constrained residues. 
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Figure 19. Molecular conformation in crystals for the 11 residue synthetic peptide 
Boc–Leu–Aib–Val–b-Gly–g–Abu–Leu–Aib–Val–Ala–Leu–Aib–OMe (ref. 61) acco-
mmodating a central b-G y–g–Abu segment. The dipeptide segments are shown on the 
right. (top) Val–b–Gly, (middle) b-Gly–g–Abu and (bottom) g–Abu–Leu. 
 
 
 The rational use of b-residues in peptide design requires an understanding of the nature 
of the local conformations, which are readily accessible. Conformational space for  
b-residues can be conveniently represented in a three dimensional f–q–y plot, in a 
simple extension of the Ramachandran analysis for -residues.58 Figure 17 shows the 
observed distribution of f, q, y values for b-residues in peptide crystal structures. Both b 
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oligopeptides and hybrid a,b-sequences are included. The conformation about the central 
C–C bond is overwhelmingly restricted to the anticipated gauche+ (g+,q = +60°) gauche– 
(g–, q = –60°) and trans (t, q = 180°) conformations. The g+ and g– conformations induce 
helical folding. Figure 18 illustrates the observed clusters in conformational space for  
b-residues incorporated into regular secondary structures. The 12-helix and 14-helix have 
been crystallographically characterised in oligomers of the constrained b-amino acid 
ACPC59 and ACHC60 (see also figure 15). b-residues can be incorporated into a-helical 
and b-sheet structures formed by predominately a-amino acid sequences. We have 
undertaken a systematic characterisation of the conformational characteristics of hybrid 
peptides containing a-, b-, and g-residues. 
 The crystal structures of the peptides Boc–Leu–Aib–Val–b–Gly–g–Abu–Leu–Aib–
Val–OMe and Boc–Leu–Aib–Val–b–Gly–g–Abu–Leu–Aib–Val–Ala–Leu–Aib–OMe 
provided the first examples of the incorporation of the bg segment into helical a-peptide 
structures.61 (In the original report61 the b-Gly residue was called b-Ala, which has been 
the trivial name used for 3-aminopropionic acid. Following the growth of the literature on 
b-residues and b-peptides, the designation b-Ala is best reserved for the b-residue 
obtained by backbone homologation of the residue Ala). Figure 19 shows the structure of 
 
 
 
 
Figure 20. (a) Molecular conformation in crystals of the helical octapeptide Boc–
Leu–Phe–Val–Aib–b–Phe–Leu–Phe–Val–OMe, which incorporates a single b-Phe 
residue. (b) View of the dipeptide segments Aib–b-Phe (top) and b-Phe–Leu 
(bottom). In both cases the NLO distance corresponding to a potential hydrogen bond 
are outside the normal limits. (c) An expanded view of Aib–b–Phe–Leu segment. Two 
C14 hydrogen bonds are observed, corresponding to the expansion of the a-helical turn 
by insertion of an additional carbon atom i to the peptide backbone. 
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Figure 21. Molecular conformation observed in crystals for peptides containing  
b-residues in the strand segments of b-hairpins (a) Boc–Leu–Val–b–Phe–Val–DPro–
Gly–Leu–b–Phe–Val–Val–OMe, (DPro–Gly: type I¢ b-turn) (ref. 62), (b) Boc–b-Phe–
b–Phe-DPro–Gly–b–Phe–b-Phe–OMe, (DPro–Gly: type II¢ b-turn) (ref. 63), (c  Boc–
Leu–Val–b–Val–DPro–Gly–b–Leu–Val–Val–OMe (DPro–Gly: type I¢ b-turn) (ref. 
58). 
 
 
the 11 residue helix, incorporating a central b-Gly–g-Abu segment. Helical folding of the 
host sequence is facilitated by the introduction of Aib residues at positions 2, 7 and 11. 
The insertion of three additional CH2 groups into the helix backbone does not have a 
major disrupting influence on the structure. Figure 19 also shows a view of the three 
dipeptide segments Val-b–G y (ab), b-Gly-g-Abu (bg) and g-Abu–Val (ga). Internal 
4 ® 1 hydrogen bonds are observed in the bg (13 atom hydrogen bonded ring, C13) and 
ga (12 atom hydrogen bonded ring, C12) segments. The backbone torsion angles at the bg 
segments are b-Gly: f = –103°, q1 = 78° and y = –107°. g-Abu: f = –121°, q1 = 57°, q2 = 
62 and y = –121°. In the eight residue peptide the corresponding values are b-Gly: f =
–130°, q1 = 76° and y = –162°. g-Abu: f = –108°, q1 = 58°, q2 = 66° and y = –169°. 
Accommodation of b- and g-residues into helical folds is achieved by adoption of 
gauche+ (g+) conformations at the additional C–C bond. An example of the insertion of a 
single b-residue into an -peptide helix is observed in the structure of the octapeptide 
Boc–Leu–Phe–Val–Aib–b–Phe–Leu–Phe–Val–OMe in crystals (unpublished). Figure 20 
shows a view of the molecular conformation. An expanded view of the aba segment is 
also shown. The dipeptide segments Aib–b–Phe (ab) and b-Phe–Val (ba) do not form 
strong 4 ® 1 hydrogen bonds, which would result in 11 atom rings. Instead hydrogen 
bonds of the 5 ® 1 type, which result in a 14 atom hydrogen bonded ring are observed in 
the aba and baa segments. The observed conformational angles for the guest b-P  
residue in the host a-peptide helix are f = –122×4°, q1 = 1×3° and y = –98×7°. 
 While relatively few examples exist of the insertion of b- and g-residues into a-peptide 
helices, incorporation into strand segments of hairpins is readily achieved. Several 
crystalline peptide hairpins, nucleated by DPro–Gly turning segments, containing  
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b-residue in the strands have been crystallographically characterized.58,62,63 Figur  21 
shows three representative b-hairpin structures containing b-residues. The insertion of b-
Phe residues in the strand segment results in a change of the polarity of the strand, as 
compared to the strands containing a-residues. In the case of b-peptide strands, adjacent 
carbonyl groups point in one direction, while the NH groups are oriented in the opposite 
direction, leading to the formation of p lar sheets in crystals. In most of the observed 
structures, the b-residues used have been -Phe, b-Val and b-Leu, with average torsion 
angles of = –113 ± 20°, q = 163 ± 7° and y = 127 ± 19° (values averaged over 10 b-
residues). An interesting distortion is observed in the crystal stru ture of the octapeptide 
Boc–Leu–Val–b–Val–DPro–Gly–b–Leu–Val–Val–OMe (figure 21). While the hairpin 
nucleated by a type I¢ DPro–Gly b-turn is clearly observed, the b-Val(3) residue adopts a  
 
 
 
 
Figure 22. Molecular conformations in crystals in four peptides containing  
the constrained g-amino acid residue gabapentin (Gpn). (a) Piv–Pro–Gpn–OH; Gpn 
f = 92×9°, q1 = –66×7°, q2 = –70×7° and y = 84×6° (b) Boc–Gly–Gpn–OH; Gpn f = 
–103×7°, q1 = –44×9°, q2 = –48×7° and y = –94×3° (c) Boc–Aib–Gpn–OH; Gpn 
f = 103×9°, q1 = –57×3°, q2 = –75×5° and y = –73×5° (d) Boc–Aib–Gpn–OMe; Gpn f= 
–102×1°, q1 = –48×2°, q2 = –50×3° and y = –90×0 (ref. 65). 
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gauche+ conformation f = –131°, q = 65° and y = –175°. Despite the g+ conformation 
about the Ca–Cb bond in b-Val(3), cross hydrogen bonding is not disturbed with a 
compensating distortion at b-Val resulting in an almost completely extended value  
(–175°) for y.58 
 b-residues can also be accommodated in the turn segments of hairpins although no 
crystal structures have yet been determined for large hairpins. The dinipecotic acid 
segment has been shown to induce hairpin formation in short tetrapeptide sequences.64 
NMR studies in solution provide evidence for the accommodation of b-Phe at the i + 2 
position of the turn segment in the synthetic peptide Boc–Leu–Val–Val–DPro–b–Phe–
Leu–Val–Val–OMe.58 In recent work, we have began exploring the use of the stereo-
chemically constrained, achiral b,b-disubstituted g-amino acid, gabapentin (1-(amino-
methyl) cyclohexaneacetic acid, Gpn) into short a-amino acid containing peptides. The 
presence of the geminal substituents at the central atom restrict the torsion angles q1 and 
q2 to ± 60°, resulting in obligatory folding of the chain upon insertion of the Gpn residue. 
Figure 22 shows the molecular conformation of four model peptides containing the Gpn 
residue.65 In each case, the local folding of the chain is clearly evident with gauche 
conformations observed about the Ca–Cb (q1) and Cb–Cg (q2) bonds. Interestingly, the 
unsubstituted d-amino acid, d-aminovaleric acid (-Ava) can be incorporated into 
designed a-amino acid structures. The insertion of d-Ava at the i + 2 position of the turn 
segment of a b-hairpin66 and into the centre of a peptide helix67 have been established by 
NMR studies of model peptides in solutions. 
 The incorporation of b- and g-amino acids into hybrid peptide sequences can impart 
proteolytic stability to biologically active peptides.68 It will be interest to design 
pharmacologically important peptides, to specially inhibit proteolysis at labile sites by 
backbone modification. In such cases the analog peptides must largely retain the confor-
mation of the parent sequence in order to manifest biological activity. The exploration of 
the effect of b- and g-residues on the conformation of host a-peptides may provide a 
rational basis for the choice of sites for insertion. 
10. Conclusion 
The use of stereochemically constrained amino acid residues can limit the range of local 
conformations of polypeptide chains, thereby nucleating folding and formation of defined 
secondary structures. This review has focused primarily on the role of a-aminoisobutyric 
acid (Aib) in promoting helix formation, D-amino acid residues in facilitating helix 
termination and DPro–Xxx segments in nucleating b-hairpin structures. The work 
reviewed has been largely based on the crystallographic characterisation of peptide 
conformations in the solid state, in the case of helices and hairpins. For multi-stranded  
b-sheets, which have thus far not yielded single crystals, two-dimensional NMR 
spectroscopy has provided firm evidence for the nature of the designed structures in 
solution. The use of b- and g-amino acids offers the possibility of extending the range of 
well defined peptide structures, beyond those normally observed in natural proteins. The 
availability of structurally well characterised peptide modules has facilitated investigation 
of side chain interactions, notably between aromatic groups69 and permitted mechanistic 
investigations of proximity effects in catalysis of biologically relevant reactions, like  
the Amadori rearrangement of glycated peptides.70 Furthermore, structurally rigid  
peptide scaffolds have provided the bases for the design of new catalytically active 
sequences.71 
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